Core Viewpoint - Tango Therapeutics, Inc. has announced a significant underwritten offering of common stock and pre-funded warrants, aiming to raise approximately $210 million to support its precision cancer medicine initiatives [1] Group 1: Offering Details - The offering consists of 21,023,337 shares of common stock priced at $8.66 each and pre-funded warrants to purchase up to 3,226,458 shares priced at $8.659 [1] - The gross proceeds from the offering are expected to be around $210 million before deducting underwriting discounts and commissions [1] - The offering is anticipated to close on or about October 24, 2025, subject to customary closing conditions [1] Group 2: Private Investment in Public Equity (PIPE) - Concurrently, Tango has entered into a PIPE agreement, selling 1,732,101 shares at the same price of $8.66 per share, expected to generate approximately $15 million [3] - The PIPE is also expected to close on or about October 24, 2025, subject to customary closing conditions [3] Group 3: Management and Regulatory Information - Leerink Partners and Cantor are acting as joint bookrunning managers for the offering [2] - The offering is made under an effective shelf registration statement previously filed with the SEC, and related documents will be available on the SEC's website [4]

Core Viewpoint - Tango Therapeutics, Inc. has announced a significant underwritten offering of common stock and pre-funded warrants, aiming to raise approximately $210 million to support its precision cancer medicine initiatives [1] Group 1: Offering Details - The offering consists of 21,023,337 shares of common stock priced at $8.66 each and pre-funded warrants to purchase up to 3,226,458 shares priced at $8.659 each [1] - The gross proceeds from the offering are expected to be around $210 million before deducting underwriting discounts and commissions [1] - The offering is expected to close on or about October 24, 2025, subject to customary closing conditions [1] Group 2: Private Investment in Public Equity (PIPE) - Concurrently, Tango has entered into a PIPE agreement, selling 1,732,101 shares at the same price of $8.66 per share, with expected gross proceeds of approximately $15 million [3] - The PIPE is led by Nextech and is also expected to close on or about October 24, 2025, subject to customary closing conditions [3] Group 3: Management and Regulatory Information - Leerink Partners and Cantor are acting as joint bookrunning managers for the offering [2] - The offering is made pursuant to an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) [4] - The securities sold in the PIPE are not registered under the Securities Act of 1933 and will require a registration statement for resale [5] Group 4: Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on discovering novel drug targets and developing precision medicine for cancer treatment [7] - The company utilizes the genetic principle of synthetic lethality to target critical areas in cancer, including tumor suppressor gene loss [7]